Literature DB >> 12369887

The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans.

P B Danielson1.   

Abstract

Cytochrome p450s comprise a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, cytochrome p450s are best know for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism. Recent advances in our understanding of cytochrome p450-mediated drug metabolism have been accelerated as a result of an increasing emphasis on functional genomic approaches to p450 research. While human cytochrome p450 databases have swelled with a flood of new human sequence variants, however, the functional characterization of the corresponding gene products has not kept pace. In response researchers have begun to apply the tools of proteomics as well as homology-based and ab initio modeling to salient questions of cytochrome p450 structure/function. This review examines the latest advances in our understanding of human cytochrome p450s.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12369887     DOI: 10.2174/1389200023337054

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  162 in total

1.  Epigenetic modification of histone 3 lysine 27: mediator subunit MED25 is required for the dissociation of polycomb repressive complex 2 from the promoter of cytochrome P450 2C9.

Authors:  Neal A Englert; George Luo; Joyce A Goldstein; Sailesh Surapureddi
Journal:  J Biol Chem       Date:  2014-11-12       Impact factor: 5.157

2.  Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice.

Authors:  Young Joo Park; Eun Kyung Lee; Yoon Kwang Lee; Do Joon Park; Hak Chul Jang; David D Moore
Journal:  Toxicol Appl Pharmacol       Date:  2012-04-03       Impact factor: 4.219

3.  Conformational transitions and redox potential shifts of cytochrome P450 induced by immobilization.

Authors:  Smilja Todorovic; Christiane Jung; Peter Hildebrandt; Daniel H Murgida
Journal:  J Biol Inorg Chem       Date:  2005-12-03       Impact factor: 3.358

4.  A support vector machine approach to classify human cytochrome P450 3A4 inhibitors.

Authors:  Jan M Kriegl; Thomas Arnhold; Bernd Beck; Thomas Fox
Journal:  J Comput Aided Mol Des       Date:  2005-03       Impact factor: 3.686

5.  Gene cloning and expression analysis of AhR and CYP4 from Pinctada martensii after exposed to pyrene.

Authors:  Junqiao Du; Chenghong Liao; Hailong Zhou; Xiaoping Diao; Yuhu Li; Pengfei Zheng; Fuqiang Wang
Journal:  Ecotoxicology       Date:  2015-02-11       Impact factor: 2.823

6.  Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug.

Authors:  Kun-Eek Kil; Anat Biegon; Yu-Shin Ding; Andre Fischer; Richard A Ferrieri; Sung Won Kim; Deborah Pareto; Michael J Schueller; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2009-02       Impact factor: 2.408

7.  Characterization of ScMat1, a putative TFIIH subunit from sugarcane.

Authors:  Agustina Gentile; Renata F Ditt; Fabio O Dias; Marcio J Da Silva; Marcelo C Dornelas; Marcelo Menossi
Journal:  Plant Cell Rep       Date:  2009-01-16       Impact factor: 4.570

Review 8.  United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.

Authors:  Woondong Jeong; James H Doroshow; Shivaani Kummar
Journal:  Curr Probl Cancer       Date:  2013 May-Jun       Impact factor: 3.187

9.  Three new alternative splicing variants of human cytochrome P450 2D6 mRNA in human extratumoral liver tissue.

Authors:  Jian Zhuge; Ying-Nian Yu
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

10.  Cytochrome P450 2AA molecular clone, expression pattern, and different regulation by fish oil and lard oil in diets of grass carp (Ctenopharyngodon idella).

Authors:  Xiao-Chen Shi; Jian Sun; Ai Jin; Hong Ji; Hai-Bo Yu; Yang Li; Xue-Xian Li; Pin Liu; Chao Li; Ji-Qin Huang
Journal:  Fish Physiol Biochem       Date:  2018-05-03       Impact factor: 2.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.